File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases

TitleFuture perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases
Authors
Issue Date2010
PublisherSchattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.com
Citation
Thrombosis And Haemostasis, 2010, v. 104 n. 1, p. 39-44 How to Cite?
AbstractRecent advances in stem cell biology have transformed the understanding of cell physiology and developmental biology such that it can now play a more prominent role in the clinical application of stem cell and regenerative medicine. Success in the generation of human induced pluripotent stem cells (iPS) as well as related emerging technology on the iPS platform provide great promise in the development of regenerative medicine. Human iPS cells show almost identical properties to human embryonic stem cells (ESC) in pluripotency, but avoid many of their limitations of use. In addition, investigations into reprogramming of somatic cells to pluripotent stem cells facilitate a deeper understanding of human stem cell biology. The iPS cell technology has offered a unique platform for studying the pathogenesis of human disease, pharmacological and toxicological testing, and cell-based therapy. Nevertheless, significant challenges remain to be overcome before the promise of human iPS cell technology can be realised. © Schattauer 2010.
Persistent Identifierhttp://hdl.handle.net/10722/163323
ISSN
2015 Impact Factor: 5.255
2015 SCImago Journal Rankings: 2.089
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLian, Qen_US
dc.contributor.authorChow, Yen_US
dc.contributor.authorEsteban, MAen_US
dc.contributor.authorPei, Den_US
dc.contributor.authorTse, HFen_US
dc.date.accessioned2012-09-05T05:30:03Z-
dc.date.available2012-09-05T05:30:03Z-
dc.date.issued2010en_US
dc.identifier.citationThrombosis And Haemostasis, 2010, v. 104 n. 1, p. 39-44en_US
dc.identifier.issn0340-6245en_US
dc.identifier.urihttp://hdl.handle.net/10722/163323-
dc.description.abstractRecent advances in stem cell biology have transformed the understanding of cell physiology and developmental biology such that it can now play a more prominent role in the clinical application of stem cell and regenerative medicine. Success in the generation of human induced pluripotent stem cells (iPS) as well as related emerging technology on the iPS platform provide great promise in the development of regenerative medicine. Human iPS cells show almost identical properties to human embryonic stem cells (ESC) in pluripotency, but avoid many of their limitations of use. In addition, investigations into reprogramming of somatic cells to pluripotent stem cells facilitate a deeper understanding of human stem cell biology. The iPS cell technology has offered a unique platform for studying the pathogenesis of human disease, pharmacological and toxicological testing, and cell-based therapy. Nevertheless, significant challenges remain to be overcome before the promise of human iPS cell technology can be realised. © Schattauer 2010.en_US
dc.languageengen_US
dc.publisherSchattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.comen_US
dc.relation.ispartofThrombosis and Haemostasisen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAnimalsen_US
dc.subject.meshCardiovascular Diseases - Diagnosis - Pathology - Physiopathology - Therapyen_US
dc.subject.meshDrug Evaluation, Preclinicalen_US
dc.subject.meshHumansen_US
dc.subject.meshInduced Pluripotent Stem Cells - Metabolism - Pathologyen_US
dc.subject.meshRegenerative Medicineen_US
dc.subject.meshTissue Therapy - Trendsen_US
dc.titleFuture perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseasesen_US
dc.typeArticleen_US
dc.identifier.emailLian, Q:qzlian@hkucc.hku.hken_US
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_US
dc.identifier.authorityLian, Q=rp00267en_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1160/TH10-05-0269en_US
dc.identifier.pmid20539907-
dc.identifier.scopuseid_2-s2.0-77954362697en_US
dc.identifier.hkuros204424-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77954362697&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume104en_US
dc.identifier.issue1en_US
dc.identifier.spage39en_US
dc.identifier.epage44en_US
dc.identifier.isiWOS:000280298300007-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridLian, Q=7003399023en_US
dc.identifier.scopusauthoridChow, Y=35784012900en_US
dc.identifier.scopusauthoridEsteban, MA=35591774300en_US
dc.identifier.scopusauthoridPei, D=7102806599en_US
dc.identifier.scopusauthoridTse, HF=7006070805en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats